Annual Accounts Receivable
$439.30 M
+$89.30 M+25.51%
31 December 2023
Summary:
Neurocrine Biosciences annual accounts receivable is currently $439.30 million, with the most recent change of +$89.30 million (+25.51%) on 31 December 2023. During the last 3 years, it has risen by +$282.20 million (+179.63%). NBIX annual accounts receivable is now at all-time high.NBIX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$481.10 M
+$12.90 M+2.76%
30 September 2024
Summary:
Neurocrine Biosciences quarterly accounts receivable is currently $481.10 million, with the most recent change of +$12.90 million (+2.76%) on 30 September 2024. Over the past year, it has increased by +$63.30 million (+15.15%). NBIX quarterly accounts receivable is now at all-time high.NBIX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +25.5% | +15.2% |
| 3 y3 years | +179.6% | +193.7% |
| 5 y5 years | +665.3% | +317.2% |
NBIX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +179.6% | at high | +193.7% |
| 5 y | 5 years | at high | +665.3% | at high | +317.2% |
| alltime | all time | at high | at high |
Neurocrine Biosciences Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $481.10 M(+2.8%) |
| June 2024 | - | $468.20 M(+3.9%) |
| Mar 2024 | - | $450.70 M(+2.6%) |
| Dec 2023 | $439.30 M(+25.5%) | $439.30 M(+5.1%) |
| Sept 2023 | - | $417.80 M(+7.8%) |
| June 2023 | - | $387.60 M(-1.0%) |
| Mar 2023 | - | $391.60 M(+11.9%) |
| Dec 2022 | $350.00 M(+88.7%) | $350.00 M(+16.2%) |
| Sept 2022 | - | $301.20 M(+8.0%) |
| June 2022 | - | $279.00 M(+5.9%) |
| Mar 2022 | - | $263.50 M(+42.0%) |
| Dec 2021 | $185.50 M(+18.1%) | $185.50 M(+13.2%) |
| Sept 2021 | - | $163.80 M(+3.3%) |
| June 2021 | - | $158.50 M(+7.2%) |
| Mar 2021 | - | $147.80 M(-5.9%) |
| Dec 2020 | $157.10 M(+24.1%) | $157.10 M(+0.1%) |
| Sept 2020 | - | $156.90 M(+5.7%) |
| June 2020 | - | $148.40 M(-0.1%) |
| Mar 2020 | - | $148.60 M(+17.4%) |
| Dec 2019 | $126.60 M(+120.5%) | $126.60 M(+9.8%) |
| Sept 2019 | - | $115.32 M(+20.9%) |
| June 2019 | - | $95.36 M(+32.5%) |
| Mar 2019 | - | $71.96 M(+25.4%) |
| Dec 2018 | $57.41 M(+84.4%) | $57.41 M(+6.1%) |
| Sept 2018 | - | $54.10 M(+26.9%) |
| June 2018 | - | $42.65 M(-4.4%) |
| Mar 2018 | - | $44.62 M(+43.4%) |
| Dec 2017 | $31.13 M(>+9900.0%) | $31.13 M(+4.4%) |
| Sept 2017 | - | $29.82 M(+390.9%) |
| June 2017 | - | $6.07 M(>+9900.0%) |
| Dec 2016 | $0.00 | $0.00(-100.0%) |
| Mar 2011 | - | $3.28 M(-37.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2010 | - | $5.22 M(-53.7%) |
| June 2010 | - | $11.28 M(+6820.2%) |
| Sept 2008 | - | $163.00 K(+8050.0%) |
| June 2008 | - | $2000.00(-83.3%) |
| Mar 2008 | - | $12.00 K(-55.6%) |
| Dec 2007 | $27.00 K(-99.6%) | $27.00 K(+50.0%) |
| Sept 2007 | - | $18.00 K(-48.6%) |
| June 2007 | - | $35.00 K(-87.2%) |
| Mar 2007 | - | $274.00 K(-96.2%) |
| Dec 2006 | $7.19 M(+738.1%) | $7.19 M(+1568.4%) |
| Sept 2006 | - | $431.00 K(+6.2%) |
| June 2006 | - | $406.00 K(-93.2%) |
| Mar 2006 | - | $5.93 M(+591.1%) |
| Dec 2005 | $858.00 K(-89.6%) | $858.00 K(-44.2%) |
| Sept 2005 | - | $1.54 M(-93.3%) |
| June 2005 | - | $22.83 M(+440.0%) |
| Mar 2005 | - | $4.23 M(-48.5%) |
| Dec 2004 | $8.21 M(-39.9%) | $8.21 M(+9.6%) |
| Sept 2004 | - | $7.49 M(+61.8%) |
| June 2004 | - | $4.63 M(+1.5%) |
| Mar 2004 | - | $4.56 M(-66.6%) |
| Dec 2003 | $13.66 M(+5430.0%) | $13.66 M(-16.7%) |
| Sept 2003 | - | $16.40 M(-49.1%) |
| June 2003 | - | $32.22 M(+8.1%) |
| Mar 2003 | - | $29.80 M(>+9900.0%) |
| Dec 2002 | $247.00 K(-97.5%) | $247.00 K(-89.7%) |
| Sept 2002 | - | $2.39 M(-12.2%) |
| June 2002 | - | $2.72 M(-44.4%) |
| Mar 2002 | - | $4.89 M(-50.8%) |
| Dec 2001 | $9.95 M | $9.95 M(+401.2%) |
| June 2001 | - | $1.99 M(+59.7%) |
| Mar 2001 | - | $1.24 M |
FAQ
- What is Neurocrine Biosciences annual accounts receivable?
- What is the all time high annual accounts receivable for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual accounts receivable year-on-year change?
- What is Neurocrine Biosciences quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly accounts receivable year-on-year change?
What is Neurocrine Biosciences annual accounts receivable?
The current annual accounts receivable of NBIX is $439.30 M
What is the all time high annual accounts receivable for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual accounts receivable is $439.30 M
What is Neurocrine Biosciences annual accounts receivable year-on-year change?
Over the past year, NBIX annual accounts receivable has changed by +$89.30 M (+25.51%)
What is Neurocrine Biosciences quarterly accounts receivable?
The current quarterly accounts receivable of NBIX is $481.10 M
What is the all time high quarterly accounts receivable for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly accounts receivable is $481.10 M
What is Neurocrine Biosciences quarterly accounts receivable year-on-year change?
Over the past year, NBIX quarterly accounts receivable has changed by +$63.30 M (+15.15%)